Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 10, 2016
DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be pre...
Nov 7, 2016
DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's third quarter 2016 fina...
Nov 3, 2016
Two advanced kidney cancer patients from a Phase 2 clinical trial maintain ongoing control of metastatic disease seven years after initiation of treatment with AGS-003 in combination with sunitinib. DURHAM, N.C., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. ...
Nov 2, 2016
DURHAM, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company is participating in the...
Oct 26, 2016
DURHAM, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced Jeff Abbey, the company's president and ch...
Oct 19, 2016
Event to be held at NASDAQ MarketSite in New York City from 8:00-11:00 a.m. Eastern Time. Immunology and kidney cancer experts to review the company's individualized immunotherapies based on the Arcelis® technology platform and discuss the treatment landscape. ...
Oct 14, 2016
DURHAM, N.C., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be presen...
Oct 3, 2016
DURHAM, N.C., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will be presenting ...
Sep 1, 2016
DURHAM, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the company will participate...
Aug 10, 2016
- Independent Data Monitoring Committee Recommended Continuation of Phase 3 ADAPT Trial of AGS-003 in Metastatic Renal Cell Carcinoma - - Closed on $29.8 million Second Tranche of March 2016 Financing - - Raised Gross Proceeds of $50.0 million in Follow-on ...
Aug 4, 2016
DURHAM, N.C., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis® technology platform, today announced that the Company's second quarter 20...
Jul 28, 2016
DURHAM, N.C., July 28, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced the pricing o...
Jul 27, 2016
DURHAM, N.C., July 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that it inten...
Jul 14, 2016
The investigator-initiated Phase 2 trial is designed to evaluate the virologic impact of the combination of the latency-reversing drug, vorinostat, and AGS-004, the company's investigational immunotherapy based on the Arcelis® technology platform. DURHAM, N.C., Ju...
Jul 11, 2016
DURHAM, N.C., July 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform...
= add release to Briefcase

Stock Quote

NASDAQ: ARGS
0.46
+ 0.05 (+13.39%)

Day High:
0.56

Day Low:
0.41

Volume:
3,451,162

4:00 PM ET on May 26, 2017
Delayed at least 20 minutes.

Tweets